Recent News

  1. JUBILANT RECEIVES FAVORABLE RULINGS FROM THE U.S. PATENT OFFICE INVALIDATING BRACCO RUBIDIUM-INFUSION-SYSTEM PATENTS Yardley, PA, February 17, 2020 – On February 7, 2020, Jubilant DraxImage Inc. and certain of its affiliates (“Jubilant”) were informed by the U.S. Patent Office that, in a lawsuit filed by Bracco Diagnostics, Inc (“Bracco”) in (...)
  2. Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime® a Product Used to Diagnose Intra-Abdominal Infection and Inflammatory Bowel Disease January 26, 2020 – Jubilant Radiopharma, a business unit of Jubilant Pharma Limited, announced today that they received approval from Health Canada for Drax Exametazime (Kit for the Preparation of (...)
  3. Jubilant Receives Favorable Ruling from the U.S. Courts for RUBY-FILL®   Yardley, PA, December 11, 2019 – On December 2, 2019, Jubilant DraxImage Inc. and certain of its affiliates (“Jubilant”) received notice of the favorable decision of the U.S. International Trade Commission (the “ITC”) in its case against Bracco Diagnostics (...)
  4. Dear Valued RUBY-FILL User, Please find here an important drug safety communication, as requested by the FDA, regarding the potential risk to high-level radiation exposure in some patients due to Sr-82 and Sr-85 breakthrough in the eluate when using an incorrect solution to elute a Rubidium Rb-82 generator and failure (...)
  5. We are pleased to announce that we have partnered with other industry leaders on a joint industrial communication to the nuclear medicine community in an effort to raise awareness regarding the potential supply of non-FDA approved products to their institutions.    
  6. Jubilant DraxImage recently participated in the Family Health Campaign in which we joined industry advocates, leaders and professionals to raise awareness of the continuously growing impact of cardiovascular disease and the growing number of deaths associated with it – 1 in 4 deaths in the U.S. is caused by heart disease and (...)